chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a female patient who on an unspecified date was vaccinated with HPV rL1 6 11 16 18 VLP vaccine (yeast). Subsequently the patient experienced dizziness and nausea within a few minutes post vaccination. Unspecified medical attention was sought. It was reported that the symptoms lasted only a few minutes. Additional information has been requested.
First dose I was exhausted, body aches, high fever and headache. The 2nd dose I had dry heaves and headache.
Swelling of the arm 5" area received DTaP and IPV in right deltoid.
I had diarrhea; I had the Moderna arm; arm swelled up all the way to my elbow; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (I had the Moderna arm), PERIPHERAL SWELLING (arm swelled up all the way to my elbow) and DIARRHOEA (I had diarrhea) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     Concomitant products included LORATADINE, AMLODIPINE, BUSPIRONE, XYLOMETAZOLINE HYDROCHLORIDE (SUDAFED [XYLOMETAZOLINE HYDROCHLORIDE]) and VITAMINS NOS for an unknown indication.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced VACCINATION SITE REACTION (I had the Moderna arm) and PERIPHERAL SWELLING (arm swelled up all the way to my elbow). On 26-Mar-2021, the patient experienced DIARRHOEA (I had diarrhea). On 29-Mar-2021, PERIPHERAL SWELLING (arm swelled up all the way to my elbow) had resolved. At the time of the report, VACCINATION SITE REACTION (I had the Moderna arm) was resolving and DIARRHOEA (I had diarrhea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient used ice, cortisone cream and Benadryl for the treatment.
4 hours after shot I had chills for 5 hours; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 20Mar2021 11:00 (Lot number: EN6204) as dose 1, single for covid-19 immunisation. Relevant medical history included: "high cholesterol" (unspecified if ongoing), notes: extremely high cholesterol, maintains around 310; "Known allergies: penicillin" (unspecified if ongoing), notes: Known allergies: Yes. Many food items, penicillin and variations, many statin drugs; "Known allergies: Yes,many food items" (unspecified if ongoing). Concomitant medication(s) included: FLAGYL [METRONIDAZOLE]; VITAMIN B2 [RIBOFLAVIN]; CRANBERRY. The following information was reported: CHILLS (non-serious) with onset 21Mar2021 15:00, outcome "recovering", described as "4 hours after shot I had chills for 5 hours". Therapeutic measures were not taken as a result of chills.  Additional information: No covid prior vaccination. No covid tested post vaccination. No other vaccine in four weeks.  No follow-up attempts are possible. No further information is expected.
01/18/22 presents to ED for "Rapid heart rate". PMHx of "developmental delay, dyslipidemia"
First Shingrix vaccine in August 2020 / Second Shingrix vaccine late due to Covid-19 restrictions; This case was reported by a consumer via call center representative and described the occurrence of social problem in a 64-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose of Shingrix received in August 2020,intramuscularly).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.  Additional details were provided as follows: The case was reported by the consumer for himself. The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix  due to Covid-19 restrictions, which led to social problem. No further information was reported. The reporter did not consented to follow up.
could not walk from the leg pain for a period of time; leg pain; numbness after the first dose of the vaccine; vertigo; nausea; vomiting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative.  A 45 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for Covid-19 immunization, reaction(s): "vertigo"; Bnt162b2, for Covid-19 immunization, reaction(s): "numbness", "nausea", "Leg pain", "vomiting". The following information was reported: GAIT DISTURBANCE (non-serious), outcome "unknown", described as "could not walk from the leg pain for a period of time"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "leg pain"; HYPOAESTHESIA (non-serious), outcome "unknown", described as "numbness after the first dose of the vaccine"; VERTIGO (non-serious), outcome "unknown", described as "vertigo"; NAUSEA (non-serious), outcome "unknown", described as "nausea"; VOMITING (non-serious), outcome "unknown", described as "vomiting".  Additional information: She could not walk from the leg pain for a period of time. The event took place after use of product.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Musclepain,joint pain,headache, and hardness  on the arm of the injection
Patient reported symptoms that may be associated with exacerbation of pre-existing CHF.  In addition, she reported a macropapular rash.  Her primary provider declined to directly link symptomatology with the two coronavirus (mRNA) vaccines.  Patient did receive dexamethasone and hydroxyzine during this period, though it is unknown if these drugs were prescribed as a result of the symptoms described.
It was reported from a male consumer that just hours post vaccination the pt became sick, developed a headache, fever, and extreme muscle pain at the injection site. Follow up information indicated that the patinet had an allergic reactio nto a dose of pneumococcal vaccine 23 polyvalent that made his arm red and swollen. The patient was later placed on therapy with rofecoxib and experienced a stiff neck, nausea, and chills. No further information is expected. Additional information has been requested.
2nd dose of Moderna was given on 02/24/21, 16 days after 1st dose, which was on 02/08/21. No adverse effects noted.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about  27-SEP-2016, a pharmacist administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 11-FEB-2017 and 04-APR-2017, the patient was treated by physicians at a hospital and physician's office for shingles and post herpetic neuralgia respectively. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
5 min after vaccine felt nauseated, lightheaded.  BP= 130/80 Laid down for 20 min, left for home.  c/o 11:00 AM swelling of tongue + lips and throat felt tight no breathing problems, rested with HOB increase for rest of day.  All symptoms gone in AM.
She denied further AE.; administered to a patient after experiencing a temperature excursion.; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medication were not reported.  On 04-OCT-2021 the patient was vaccinated with with improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) 0.5 ml, lot # T013204 was confirmed to be valid with expiration date 03-DEC-2021 (route of administration, anatomical location were not reported) for prophylaxis. The administered dose underwent a temperature excursion of 50.5 degrees Fahrenheit for 30 minutes. There were no previous temperature excursions. No additional adverse effect was reported.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2110USA007288: US-009507513-2110USA007310: US-009507513-2110USA007316:
10FEB97 c/o sore throat, runny nose, 10FEB97 t99.8;11FEB97 cough, nasal congestion, cough;MD to examine throat cult ordered positive influenza A on 11FEB97;
On 10/10/14 FLUMIST was given to patient, patient appears to have no adverse reaction to vaccine while in clinic. On 10/11/14 patient was seen at ED for complaints of facial swelling and felt warm. Mom gave ZYRTEC at home. Dr reported no swelling or difficulty breathing on exam.
Pneumovax given right deltoid, by PM pt developed erythema, swelling, pain at injection site. Developed fever to 102 degrees 24 hours later with erythema and swelling to entire deltoid region. 48 hours later all sx resolved except minor erythema and resolving swelling. Pt placed on Keflex 500mg TID.
Patient experienced flu-like symptoms starting 11/12/10. Had an injection of novocaine to have mole removed on 11/12/10. Had skin around right eye swollen on morning of 11/13/10 and corner of left eye had started to swell too.
11/6/2013 1st signs 11/7/2013. Palpitations heart and right side of neck, night and day pulsating across back above R hip - low pulse 42-44 beat per min. I have a nervous system disorder. I read it after the shot.
This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patients had been administered with the Moderna vaccine which were beyond the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) in a 22-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 042J21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Mar-2022, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 08-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patients had been administered with the Moderna vaccine which were beyond the 30 day beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patients had been administered with the Moderna vaccine which were beyond the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patients had been administered with the Moderna vaccine which were beyond the 30 day beyond use date).    No concomitant medication was reported. Patient received vaccine from lot 042J21A with a BUD of 17-Feb-2022. The time for expiry date was reported as 12 am. No treatment medication was reported.
Headache, Arthralgia, Fever, LITTLE SORE THROAT, FATIGUE, PAIN/SWELLING INJ SITE Narrative:
In order of occurrence: Chills/Face and neck hot and itchy, red rash on face Back itchy, red rash across back Head itchy, can't tell if a rash Bad arm pain to touch, not usual shot arm pain, couldn't lay on left side to sleep Cold all night, used 2 blankets instead of usual 1; fitful sleep As of this writing: arm pain better but minor arm redness/swelling; face and neck hot; neck/back/head itchy, rash on neck/back but not as red as yesterday.  Feel cold.  Note that after my shot I was out until about 4:30 pm.  While out, I noticed that my face and neck felt hot and my neck was getting itchy, but I did not check it.  After returning home, the itchiness, chills. etc. slowly increased until at 6:30 pm I was very
Delayed Arthus Response began 3/11 and continues to increase on 3/12/2021.  Vaccination date 3/3/2021. Redness/swelling/heat/pain 12 cm induration around injection area @ 9:30AM 3/12.  Area of induration marked for monitoring.
Began to feel extreme soreness at injection site right arm, on 10/24/2010 experienced general malaise, sweating/cold, noted 6 red hive like lesions on right arm (not itchy), felt poorly, T98.4, on 10/25/10 lesions on right arm extending into axillae, seen by NP at PCP's practice, provider felt that symptoms likely related to vaccine and recommended that report should be made to VAERS. No treatment prescribed at that time. On 10/26/10 states has HA and sinus pressure, lesions on right arm are resolving.
The next day started with severe headache, myalgias, arthralgias. Then following day started with nuchal rigidity, photosensitivity and sound sensitivity. I had aseptic meningitis and required oral corticosteroids because Advil 800mg every 6 hours and Tylenol Q4 hours did not help. It took 1 month before my headaches resolved.
RASH STARTED ON 5/10/2009 FROM FACE COVERED ALL LIMBS BY 5/11/2009
Vaccine clinic was run by a school. The staff did NOT provide a Covide vaccine card after the shot was administered. They wrote the name and lot # on an unopened bandaid and gave it to patient as "proof" of vaccination. This is her booster (3rd) shot.
Pt recvd Influenza A&B vax on 8NOV91 & 12NOV91 aobut 4PM pt devel a droopy mouth on rt side; Pt consulted MD & was referred to neurologist who dx bells palsy;
Pt received second dose of Pfizer after having received two doses of Moderna on 3/4/21 and 4/1/21, as well as initial dose of Pfizer 5/18/21
trouble getting out of bed; pain in his arm; head felt weird; wobbly on his feet; This spontaneous case was reported by a consumer and describes the occurrence of DYSSTASIA (trouble getting out of bed), PAIN IN EXTREMITY (pain in his arm), HEAD DISCOMFORT (head felt weird) and LIMB DISCOMFORT (wobbly on his feet) in an 86-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Feb-2021, the patient experienced DYSSTASIA (trouble getting out of bed), PAIN IN EXTREMITY (pain in his arm), HEAD DISCOMFORT (head felt weird) and LIMB DISCOMFORT (wobbly on his feet). At the time of the report, DYSSTASIA (trouble getting out of bed), PAIN IN EXTREMITY (pain in his arm), HEAD DISCOMFORT (head felt weird) and LIMB DISCOMFORT (wobbly on his feet) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment details was reported.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up document was received. The outcome of adverse event was updated to recovered/resolved. It contains significant information.
pt recv vax;noted hives & swelling approx 10:30;did not respond to anyone until 12:30;c/o swelling of eyes & lips;
Subsequent to receiving two doses of varicella virus vaccine live, the pt experienced a varicella like rash with redness at the injection site.
Treatment of COVID-19; Treatment of COVID-19; Interchange of vaccine products: Moderna COVID-19 Vaccine (dose 1, 2, 4, and 5) and BNT162B2 (dose 3); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Nov2021 as dose 3 (initial pfizer dose), single (Lot number: FD0809) at the age of 52 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 10Feb2021 as dose 1, single (Lot number: 013M20A), in left arm, on 10Mar2021 as dose 2, single (Lot number: 001B21A), in left arm, on 15Apr2022 as dose 4 (booster), single (Lot number: 041J21A), in left arm and on 08Sep2022 as dose 5 (booster), single (Lot number: A57144B), in left arm for covid-19 immunisation. The patient's relevant medical history included: "none (besides ADHD)" (unspecified if ongoing), notes: Other medical history: none (besides ADHD). Concomitant medication(s) included: ADDERALL. Past drug history included: Clindamycin, reaction(s): "Known allergies: Clindamycin", notes: Known allergies: Clindamycin; Azithromycin, reaction(s): "Known allergies: Azithromycin", notes: Known allergies: Azithromycin. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 22Nov2021, outcome "not recovered", described as "Interchange of vaccine products: Moderna COVID-19 Vaccine (dose 1, 2, 4, and 5) and BNT162B2 (dose 3)"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 06Nov2022, outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (06Nov2022) Positive, notes: initial positive test & symptoms were Day 0; (15Nov2022) Negative, notes: testing negative on Day 9 and Day 10; (16Nov2022) Negative, notes: testing negative on Day 9 and Day 10; (17Nov2022) Positive, notes: Tested positive for COVID on Day 11. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid from 08Nov2022 to 13Nov2022.
This spontaneous report as received from a nurse practitioner refers to a 18 months old patient of unknown gender. No information on patient's medical history or concurrent conditions was provided. On 15-JAN-2015, the patient was vaccinated with the dose of LIQUID PEDVAXHIB lot # K008874 (dose, strength, route of administration and expiration date were not reported) which had temperature excursion. No information on patient's concomitant medication was provided. This is one of several reports from the same reporter. Additional information has been requested.
pt was here with spouse to get second dose administered. she did not share with me that she had been anxious and nervous all day about receiving it. i gave hers first then gave her spouse. as i was finishing up with him seconds later she said she was going to pass out.  i advised her to take deep breaths in through her nose and out her mouth, take off her mask and lean back in her chair after offering to lie her down on the floor which she refused.  she then proceeded to pass out and become unresponsive.  when she didnt come to after a minute or two, i had her husband come to her while i called EMS.  during that time she had what seemed like a seizure (was determined by EMS to not be a real seizure) where she thrashed about for a few seconds. while i was on the phone with 911 she came to and was awake and alert but not ok. EMS arrived and evaluated her. they offered to take her to the hospital but she refused. they determined that it was a combination of anxiety and panic about receiving the second shot (though she did well with the first) and having not eaten all day (while being anemic and having hypoglycemia)
Redness and swelling at site of injection, warm to touch. Tx with cold compress, Tylenol. Time approx. 1 day post vaccines.
feverish, somnolent for two days, body aches, fatigue, shoulder pain at injection site
A dose of Moderna was administered when it should not have been. The patient was contacted the following week.
This spontaneous report as received from a certified medical assistant, refers to an unknown number of patients of unknown demographics. The patient's concurrent conditions and medical history were not provided. On an unknown date in 2013, an unspecified number of patients received improperly stored Vaccine For Children (VFC) doses of RECOMBIVAX HB (dose, route, lot and expiration date were not reported) exposed to 20F and 30F on multiple occasions, from 22-SEP-2013 until 20-DEC-2013 (for 122 days). No adverse effects were reported (the reporter stated that the vaccines administered were RECOMBIVAX HB and VAQTA but on a second call was reported that no doses of VAQTA were involved in this excursion. This is the one of two reports from the same source MARRS # 1301USA002057. Additional information has been requested.
The first dose was given on 25-Mar-2021 and the second dose on 3-May-2021; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The first dose was given on 25-Mar-2021 and the second dose on 3-May-2021) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039B21A and 044A21A) for COVID-19 vaccination. Concurrent medical conditions included Autoimmune disorder.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The first dose was given on 25-Mar-2021 and the second dose on 3-May-2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The first dose was given on 25-Mar-2021 and the second dose on 3-May-2021) outcome was unknown.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. No concomitant medications reported. No treatment reported   This case was linked to MOD-2022-613556 (Patient Link).
Five minutes after receiving the vaccination (14:50) , the patient developed hives on the right side of her neck and around the vaccination site on the left arm.  25 mg (10 ml) of liquid Benadryl given orally at 15:45. Hives resolved by 16:15.